Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study

•This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored. The field of translat...

Full description

Saved in:
Bibliographic Details
Published inNeuromuscular disorders : NMD Vol. 29; no. 4; pp. 261 - 268
Main Authors Ricotti, V., Selby, V., Ridout, D., Domingos, J., Decostre, V., Mayhew, A., Eagle, M., Butler, J., Guglieri, M., Van der Holst, M., Jansen, M., Verschuuren, J.J.G.M., de Groot, I.J.M., Niks, E.H., Servais, L., Straub, V., Voit, T., Hogrel, J.Y., Muntoni, F.
Format Journal Article Web Resource
LanguageEnglish
Published England Elsevier B.V 01.04.2019
Subjects
Online AccessGet full text
ISSN0960-8966
1873-2364
1873-2364
DOI10.1016/j.nmd.2019.02.002

Cover

Loading…
Abstract •This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored. The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5–18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [−7.44,−0.72], p = 0.02 in ambulant; 4.81, 95% CI [−6.79,−2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [−6.48,−4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [−4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force −5.51%, 95% CI [−6.54,−4.48], p < 0.001 in ambulant and a slower decline −2.86%; 95% CI −3.29,−2.43, p < 0.001, in non-ambulant; pinch force: −2.66%, 95% CI [−3.82,−1.51], p < 0.001 in ambulant and −2.23%, 95% CI [−2.92,−1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
AbstractList The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
•This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and grip force are reported.•A composite score combining respiratory outcomes, upper limb function and strength is explored. The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5–18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [−7.44,−0.72], p = 0.02 in ambulant; 4.81, 95% CI [−6.79,−2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [−6.48,−4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [−4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force −5.51%, 95% CI [−6.54,−4.48], p < 0.001 in ambulant and a slower decline −2.86%; 95% CI −3.29,−2.43, p < 0.001, in non-ambulant; pinch force: −2.66%, 95% CI [−3.82,−1.51], p < 0.001 in ambulant and −2.23%, 95% CI [−2.92,−1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n = 60) to non-ambulant (n = 29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p = 0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly studied in ambulant patients. A paucity of studies focus on measures that capture the non-ambulant stage of the disease, and the transition between the ambulant and non-ambulant phase. In this prospective natural history study, we report the results of a comprehensive assessment of respiratory, upper limb function and upper limb muscle strength in a group of 89 DMD boys followed in 3 European countries, 81 receiving corticosteroids, spanning a wide age range (5-18 years) and functional abilities, from ambulant (n=60) to non-ambulant (n=29). Respiratory decline could be detected in the early ambulatory phase using Peak Expiratory Flow percentage predicted (PEF%), despite glucocorticoid use (mean annual decline: 4.08, 95% CI [-7.44,-0.72], p=0.02 in ambulant; 4.81, 95% CI [-6.79,-2.82], p < 0.001 in non-ambulant). FVC% captured disease progression in non-ambulant DMD subjects, with an annual loss of 5.47% (95% CI [-6.48,-4.45], p < 0.001). Upper limb function measured with the Performance of Upper Limb (PUL 1.2) showed an annual loss of 4.13 points (95% CI [-4.79,3.47], p < 0.001) in the non-ambulant cohort. Measures of upper limb strength (MyoGrip and MyoPinch) showed a continuous decline independent of the ambulatory status, when reported as percentage predicted (grip force -5.51%, 95% CI [-6.54,-4.48], p < 0.001 in ambulant and a slower decline -2.86%; 95% CI -3.29,-2.43, p < 0.001, in non-ambulant; pinch force: -2.66%, 95% CI [-3.82,-1.51], p < 0.001 in ambulant and -2.23%, 95% CI [-2.92,-1.53], p < 0.001 in non-ambulant). Furthermore, we also explored the novel concept of a composite endpoint by combining respiratory, upper limb function and force domains: we were able to identify clear clinical progression in patients in whom an isolated measurement of only one of these domains failed to appreciate the yearly change. Our study contributes to the field of natural history of DMD, linking the ambulant and non-ambulant phases of the disease, and suggests that composite scores should be explored further.
Author Ridout, D.
Mayhew, A.
Butler, J.
Jansen, M.
Verschuuren, J.J.G.M.
Ricotti, V.
Eagle, M.
Decostre, V.
Voit, T.
Guglieri, M.
Niks, E.H.
Van der Holst, M.
Muntoni, F.
Domingos, J.
de Groot, I.J.M.
Selby, V.
Servais, L.
Straub, V.
Hogrel, J.Y.
Author_xml – sequence: 1
  givenname: V.
  surname: Ricotti
  fullname: Ricotti, V.
  email: v.ricotti@ucl.ac.uk
  organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK
– sequence: 2
  givenname: V.
  surname: Selby
  fullname: Selby, V.
  organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK
– sequence: 3
  givenname: D.
  surname: Ridout
  fullname: Ridout, D.
  organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK
– sequence: 4
  givenname: J.
  surname: Domingos
  fullname: Domingos, J.
  organization: Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, London, UK
– sequence: 5
  givenname: V.
  surname: Decostre
  fullname: Decostre, V.
  organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France
– sequence: 6
  givenname: A.
  surname: Mayhew
  fullname: Mayhew, A.
  organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK
– sequence: 7
  givenname: M.
  surname: Eagle
  fullname: Eagle, M.
  organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK
– sequence: 8
  givenname: J.
  surname: Butler
  fullname: Butler, J.
  organization: Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, London, UK
– sequence: 9
  givenname: M.
  surname: Guglieri
  fullname: Guglieri, M.
  organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK
– sequence: 10
  givenname: M.
  orcidid: 0000-0002-0797-5711
  surname: Van der Holst
  fullname: Van der Holst, M.
  organization: Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 11
  givenname: M.
  surname: Jansen
  fullname: Jansen, M.
  organization: Department of Rehabilitation, Donders Centre of Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
– sequence: 12
  givenname: J.J.G.M.
  orcidid: 0000-0002-4572-1501
  surname: Verschuuren
  fullname: Verschuuren, J.J.G.M.
  organization: Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 13
  givenname: I.J.M.
  surname: de Groot
  fullname: de Groot, I.J.M.
  organization: Department of Rehabilitation, Donders Centre of Neuroscience, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
– sequence: 14
  givenname: E.H.
  orcidid: 0000-0001-5892-5143
  surname: Niks
  fullname: Niks, E.H.
  organization: Leiden University Medical Centre, Leiden, The Netherlands
– sequence: 15
  givenname: L.
  surname: Servais
  fullname: Servais, L.
  organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France
– sequence: 16
  givenname: V.
  surname: Straub
  fullname: Straub, V.
  organization: John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle, UK
– sequence: 17
  givenname: T.
  surname: Voit
  fullname: Voit, T.
  organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK
– sequence: 18
  givenname: J.Y.
  orcidid: 0000-0003-0045-7505
  surname: Hogrel
  fullname: Hogrel, J.Y.
  organization: Groupe Hospitalier Pitié Salpêtrière, Institut de Myologie, Paris, France
– sequence: 19
  givenname: F.
  surname: Muntoni
  fullname: Muntoni, F.
  email: f.muntoni@ucl.ac.uk
  organization: NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health, Great Ormond Street Hospital Trust, University College London, London, UK
BackLink https://www.ncbi.nlm.nih.gov/pubmed/30852071$$D View this record in MEDLINE/PubMed
BookMark eNqFkctu1DAUhiNURKeFB2CDvGSTwZeME8OqKlepEhKCteXYJx0PiR18aZWn4VVxmJZFF2Vl6-j7juz_P6tOnHdQVS8J3hJM-JvD1k1mSzERW0y3GNMn1YZ0Lasp481JtcGC47oTnJ9WZzEeMCa7lrfPqlOGux3FLdlUv79BnG1QyYcFKWdQnmcIaLRTj4bsdLLeIRWRz0n7CdAEKuYAEdkynvo8Kpf-euVp9b9BzP0BdIro1qY9ep_1Hpwrco66AAGZJabg5_3yFl2gOfg4F9rerMSYrAaXAqCYslmeV08HNUZ4cXeeVz8-fvh--bm--vrpy-XFVa2bpk11Nwx6IGqgDKAhuhVCGGi5Yo3oYQDd4p3mxHDomTCs31GiFJB-6BojmBgIO6_Yce9o4RqkD72VN1R6ZY_3PF5LpWUPklLeSdo0mK3W66NV_vArQ0xyslHDWEIAn6OkRGBCMecr-uoOzf0ERs7BTios8r6KArRHQJc8YoBBapvUmn8Kyo6SYLmWLg-ylC7X0iWmspReTPLAvF_-mPPu6EAJ9cZCkFFbcBqMDaULabx91BYPbD1aZ7Uaf8LyH_cPHZvcTA
CitedBy_id crossref_primary_10_1159_000514730
crossref_primary_10_3233_JND_230019
crossref_primary_10_1016_j_nmd_2021_07_015
crossref_primary_10_1016_j_omtm_2020_06_016
crossref_primary_10_1089_nat_2021_0043
crossref_primary_10_1002_acn3_51046
crossref_primary_10_3233_JND_210746
crossref_primary_10_1111_ene_16267
crossref_primary_10_1515_jpem_2025_0061
crossref_primary_10_2217_epi_2020_0052
crossref_primary_10_1007_s00115_020_01019_3
crossref_primary_10_1097_PEP_0000000000000922
crossref_primary_10_1186_s13023_021_02047_1
crossref_primary_10_1016_j_nmd_2023_10_003
crossref_primary_10_1038_s41591_022_02045_1
crossref_primary_10_3390_biom13071108
crossref_primary_10_3390_proteomes12010004
crossref_primary_10_1212_WNL_0000000000011051
crossref_primary_10_1371_journal_pone_0239064
crossref_primary_10_1055_s_0042_1758757
crossref_primary_10_3390_ijerph192315675
crossref_primary_10_1016_j_nmd_2019_10_008
crossref_primary_10_1590_1984_0462_2021_39_2020045
crossref_primary_10_1212_WNL_0000000000013246
crossref_primary_10_3389_fgene_2021_759994
crossref_primary_10_1016_j_nmd_2023_07_003
crossref_primary_10_1111_echo_15460
crossref_primary_10_1016_j_bjpt_2020_05_012
crossref_primary_10_3390_children10040746
crossref_primary_10_1038_s41582_023_00823_0
crossref_primary_10_1007_s00424_021_02623_1
crossref_primary_10_1007_s00415_020_09800_9
crossref_primary_10_1148_radiol_2020192210
Cites_doi 10.1371/journal.pone.0162542
10.1002/ana.23528
10.1016/j.nmd.2012.10.022
10.1016/S1474-4422(09)70271-6
10.1016/S0140-6736(15)60025-3
10.1371/journal.pone.0199223
10.1016/j.nmd.2015.07.009
10.1371/journal.pone.0083400
10.1183/09031936.00080312
10.1016/j.nmd.2011.02.016
10.1016/j.nmd.2013.05.008
10.1212/WNL.0000000000002891
10.1016/j.jacc.2016.02.081
10.1016/S1474-4422(18)30025-5
10.1002/mus.24894
10.1152/physrev.00028.2001
10.1002/ppul.10217
10.1164/rccm.201703-0507WS
10.1111/dmcn.12213
10.1183/09031936.05.00034805
10.1542/peds.2018-0333J
10.1016/j.nmd.2013.11.014
10.1002/ppul.22688
10.3233/JND-140002
10.1186/s12891-015-0612-4
10.1016/S1474-4422(18)30026-7
10.3233/JND-150100
10.1016/j.nmd.2018.07.004
10.1002/ppul.22847
10.1177/0883073810371004
10.1002/mus.25089
10.1002/ppul.23172
10.1016/S0960-8966(02)00140-2
10.1016/S1474-4422(18)30024-3
10.1212/WNL.0000000000002464
ContentType Journal Article
Web Resource
Copyright 2019 Elsevier B.V.
Copyright © 2019 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2019 Elsevier B.V.
– notice: Copyright © 2019 Elsevier B.V. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
Q33
DOI 10.1016/j.nmd.2019.02.002
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Université de Liège - Open Repository and Bibliography (ORBI)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE


Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1873-2364
EndPage 268
ExternalDocumentID oai_orbi_ulg_ac_be_2268_244031
30852071
10_1016_j_nmd_2019_02_002
S0960896618313798
Genre Research Support, Non-U.S. Gov't
Multicenter Study
Journal Article
GeographicLocations Europe
GeographicLocations_xml – name: Europe
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
29N
4.4
457
4G.
53G
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABMZM
ABTEW
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACIUM
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADVLN
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRLJ
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HDW
HMK
HMO
HMQ
HVGLF
HZ~
IHE
J1W
KOM
LX8
M29
M2V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OP~
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SSH
SSN
SSZ
T5K
UHS
UNMZH
WUQ
Z5R
~G-
AACTN
AADPK
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
ZA5
AAYXX
AGRNS
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
Q33
ID FETCH-LOGICAL-c447t-8ffcf1af23ee41c7999de76a349befec705c61d6eb39d3b521aae1bf84d939f13
IEDL.DBID .~1
ISSN 0960-8966
1873-2364
IngestDate Fri Jul 18 15:30:46 EDT 2025
Thu Jul 10 23:00:28 EDT 2025
Thu Apr 03 06:58:30 EDT 2025
Thu Apr 24 22:55:15 EDT 2025
Tue Jul 01 01:07:19 EDT 2025
Fri Feb 23 02:13:50 EST 2024
Tue Aug 26 16:46:51 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords pulmonary function
peak expiratory flow
Composite endpoint
Upper limb function and strength
Duchenne muscular dystrophy
forced vital capacity
Language English
License Copyright © 2019 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c447t-8ffcf1af23ee41c7999de76a349befec705c61d6eb39d3b521aae1bf84d939f13
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
scopus-id:2-s2.0-85062401627
ORCID 0000-0002-4572-1501
0000-0001-5892-5143
0000-0003-0045-7505
0000-0002-0797-5711
PMID 30852071
PQID 2190120661
PQPubID 23479
PageCount 8
ParticipantIDs liege_orbi_v2_oai_orbi_ulg_ac_be_2268_244031
proquest_miscellaneous_2190120661
pubmed_primary_30852071
crossref_citationtrail_10_1016_j_nmd_2019_02_002
crossref_primary_10_1016_j_nmd_2019_02_002
elsevier_sciencedirect_doi_10_1016_j_nmd_2019_02_002
elsevier_clinicalkey_doi_10_1016_j_nmd_2019_02_002
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate April 2019
2019-04-00
20190401
2019-04
PublicationDateYYYYMMDD 2019-04-01
PublicationDate_xml – month: 04
  year: 2019
  text: April 2019
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Neuromuscular disorders : NMD
PublicationTitleAlternate Neuromuscul Disord
PublicationYear 2019
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Seferian, Moraux, Annoussamy (bib0034) 2015; 10
Ricotti, Evans, Sinclair (bib0041) 2016; 11
Moxley, Pandya, Ciafaloni, Fox, Campbell (bib0005) 2010; 25
Buyse, Goemans, van den Hauwe (bib0017) 2011; 21
Hogrel, Wary, Moraux (bib0040) 2016; 86
Excellence N-NIfHaC. Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene. In: Excellence N-N I f H a C, 2016.
Connolly, Florence, Zaidman (bib0038) 2016; 54
Matthews, Brassington, Kuntzer, Jichi, Manzur (bib0013) 2016; 5
Buyse, Voit, Schara (bib0019) 2015; 385
Birnkrant, Bushby, Bann (bib0010) 2018; 17
Mayer, Finkel, Rummey (bib0037) 2015; 50
Apkon, Alman, Birnkrant (bib0006) 2018; 142
Pane, Coratti, Brogna (bib0033) 2018; 13
Blake, Weir, Newey, Davies (bib0004) 2002; 82
LoMauro, D'Angelo, Aliverti (bib0009) 2015; 11
Eagle, Baudouin, Chandler, Giddings, Bullock, Bushby (bib0007) 2002; 12
Servais, Deconinck, Moraux (bib0028) 2013; 23
(bib0035) 2017
2017.
Pane, Mazzone, Fanelli (bib0024) 2014; 24
McDonald, Gordish-Dressman, Henricson (bib0021) 2018; 28
Bushby, Finkel, Birnkrant (bib0027) 2010; 9
Domenech-Clar, Lopez-Andreu, Compte-Torrero (bib0031) 2003; 35
Han, de Bie, Nicorici (bib0026) 2016; 53
Finder, Mayer, Sheehan (bib0020) 2017; 196
Bello, Morgenroth, Gordish-Dressman (bib0043) 2016; 87
Pane, Mazzone, Sormani (bib0025) 2014; 9
Birnkrant, Bushby, Bann (bib0011) 2018; 17
Ricotti, Ridout, Pane (bib0042) 2016; 87
Hogrel (bib0029) 2015; 16
Buyse, Voit, Schara (bib0039) 2015; 385
Mendell, Shilling, Leslie (bib0002) 2012; 71
Buyse, Goemans, van den Hauwe, Meier (bib0018) 2013; 48
Pane, Fanelli, Mazzone (bib0023) 2015; 25
Kamdar, Garry (bib0008) 2016; 67
Ellis, Vroom, Muntoni (bib0003) 2013; 23
Mayhew, Mazzone, Eagle (bib0022) 2013; 55
Jean, Mah, Dykeman, Day, Pringsheim, Jette (bib0001) 2014; 24
Quanjer, Stanojevic, Cole (bib0032) 2012; 40
Birnkrant, Bushby, Bann (bib0012) 2018; 17
Miller, Hankinson, Brusasco (bib0030) 2005; 26
van den Bergen, Ginjaar, Niks, Aartsma-Rus, Verschuuren (bib0044) 2014; 1
Servais, Montus, Guiner (bib0045) 2015; 2
(bib0016) 2016
Khirani, Ramirez, Aubertin (bib0036) 2014; 49
Administration USFaD
Han (10.1016/j.nmd.2019.02.002_bib0026) 2016; 53
(10.1016/j.nmd.2019.02.002_bib0016) 2016
Apkon (10.1016/j.nmd.2019.02.002_bib0006) 2018; 142
Hogrel (10.1016/j.nmd.2019.02.002_bib0040) 2016; 86
Domenech-Clar (10.1016/j.nmd.2019.02.002_bib0031) 2003; 35
Moxley (10.1016/j.nmd.2019.02.002_bib0005) 2010; 25
Bushby (10.1016/j.nmd.2019.02.002_bib0027) 2010; 9
Mayer (10.1016/j.nmd.2019.02.002_bib0037) 2015; 50
Eagle (10.1016/j.nmd.2019.02.002_bib0007) 2002; 12
Kamdar (10.1016/j.nmd.2019.02.002_bib0008) 2016; 67
Buyse (10.1016/j.nmd.2019.02.002_bib0018) 2013; 48
Pane (10.1016/j.nmd.2019.02.002_bib0024) 2014; 24
Birnkrant (10.1016/j.nmd.2019.02.002_bib0011) 2018; 17
Pane (10.1016/j.nmd.2019.02.002_bib0033) 2018; 13
Ellis (10.1016/j.nmd.2019.02.002_bib0003) 2013; 23
Seferian (10.1016/j.nmd.2019.02.002_bib0034) 2015; 10
Buyse (10.1016/j.nmd.2019.02.002_bib0017) 2011; 21
Pane (10.1016/j.nmd.2019.02.002_bib0023) 2015; 25
Hogrel (10.1016/j.nmd.2019.02.002_bib0029) 2015; 16
(10.1016/j.nmd.2019.02.002_bib0035) 2017
Mayhew (10.1016/j.nmd.2019.02.002_bib0022) 2013; 55
McDonald (10.1016/j.nmd.2019.02.002_bib0021) 2018; 28
Buyse (10.1016/j.nmd.2019.02.002_bib0039) 2015; 385
Miller (10.1016/j.nmd.2019.02.002_bib0030) 2005; 26
Quanjer (10.1016/j.nmd.2019.02.002_bib0032) 2012; 40
Servais (10.1016/j.nmd.2019.02.002_bib0028) 2013; 23
Buyse (10.1016/j.nmd.2019.02.002_bib0019) 2015; 385
Finder (10.1016/j.nmd.2019.02.002_bib0020) 2017; 196
10.1016/j.nmd.2019.02.002_bib0015
Khirani (10.1016/j.nmd.2019.02.002_bib0036) 2014; 49
Birnkrant (10.1016/j.nmd.2019.02.002_bib0010) 2018; 17
10.1016/j.nmd.2019.02.002_bib0014
Pane (10.1016/j.nmd.2019.02.002_bib0025) 2014; 9
Mendell (10.1016/j.nmd.2019.02.002_bib0002) 2012; 71
Blake (10.1016/j.nmd.2019.02.002_bib0004) 2002; 82
Ricotti (10.1016/j.nmd.2019.02.002_bib0042) 2016; 87
Servais (10.1016/j.nmd.2019.02.002_bib0045) 2015; 2
Matthews (10.1016/j.nmd.2019.02.002_bib0013) 2016; 5
Jean (10.1016/j.nmd.2019.02.002_bib0001) 2014; 24
Birnkrant (10.1016/j.nmd.2019.02.002_bib0012) 2018; 17
Connolly (10.1016/j.nmd.2019.02.002_bib0038) 2016; 54
Ricotti (10.1016/j.nmd.2019.02.002_bib0041) 2016; 11
LoMauro (10.1016/j.nmd.2019.02.002_bib0009) 2015; 11
van den Bergen (10.1016/j.nmd.2019.02.002_bib0044) 2014; 1
Bello (10.1016/j.nmd.2019.02.002_bib0043) 2016; 87
References_xml – year: 2016
  ident: bib0016
  article-title: FDA Grants Accelerated Approval to First Drug for Duchenne Muscular Dystrophy
– volume: 48
  start-page: 912
  year: 2013
  end-page: 920
  ident: bib0018
  article-title: Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
– volume: 23
  start-page: 682
  year: 2013
  end-page: 689
  ident: bib0003
  article-title: 195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14–16th December, 2012, Naarden, The Netherlands
  publication-title: Neuromuscul. Disord.
– volume: 21
  start-page: 396
  year: 2011
  end-page: 405
  ident: bib0017
  article-title: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial
  publication-title: Neuromuscul. Disord.
– volume: 86
  start-page: 1022
  year: 2016
  end-page: 1030
  ident: bib0040
  article-title: Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy
  publication-title: Neurology
– volume: 35
  start-page: 126
  year: 2003
  end-page: 132
  ident: bib0031
  article-title: Maximal static respiratory pressures in children and adolescents
  publication-title: Pediatr. Pulmonol.
– volume: 23
  start-page: 139
  year: 2013
  end-page: 148
  ident: bib0028
  article-title: Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients
  publication-title: Neuromuscul. Disord.
– volume: 11
  start-page: 1475
  year: 2015
  end-page: 1488
  ident: bib0009
  article-title: Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options
  publication-title: Ther. Clin. Risk Manag.
– reference: . 2017.
– volume: 28
  start-page: 897
  year: 2018
  end-page: 909
  ident: bib0021
  article-title: Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids
  publication-title: Neuromuscul. Disord.
– volume: 385
  start-page: 1748
  year: 2015
  end-page: 1757
  ident: bib0039
  article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
  publication-title: Lancet
– volume: 24
  start-page: 201
  year: 2014
  end-page: 206
  ident: bib0024
  article-title: Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy
  publication-title: Neuromuscul. Disord.
– reference: Administration USFaD,
– volume: 87
  start-page: 401
  year: 2016
  end-page: 409
  ident: bib0043
  article-title: DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
  publication-title: Neurology
– volume: 55
  start-page: 1038
  year: 2013
  end-page: 1045
  ident: bib0022
  article-title: Development of the performance of the upper limb module for Duchenne muscular dystrophy
  publication-title: Dev. Med. Child Neurol.
– volume: 40
  start-page: 1324
  year: 2012
  end-page: 1343
  ident: bib0032
  article-title: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
  publication-title: Eur. Respir. J.
– year: 2017
  ident: bib0035
  article-title: Stata Statistical Software
– volume: 71
  start-page: 304
  year: 2012
  end-page: 313
  ident: bib0002
  article-title: Evidence-based path to newborn screening for Duchenne muscular dystrophy
  publication-title: Ann. Neurol.
– volume: 50
  start-page: 487
  year: 2015
  end-page: 494
  ident: bib0037
  article-title: Characterization of pulmonary function in Duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
– volume: 54
  start-page: 681
  year: 2016
  end-page: 689
  ident: bib0038
  article-title: Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up
  publication-title: Muscle Nerve
– volume: 2
  start-page: 269
  year: 2015
  end-page: 279
  ident: bib0045
  article-title: Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype
  publication-title: J. Neuromuscul. Dis.
– volume: 17
  start-page: 445
  year: 2018
  end-page: 455
  ident: bib0012
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
  publication-title: Lancet Neurol.
– volume: 26
  start-page: 319
  year: 2005
  end-page: 338
  ident: bib0030
  article-title: Standardisation of spirometry
  publication-title: Eur. Respir. J.
– volume: 142
  start-page: S82
  year: 2018
  end-page: S89
  ident: bib0006
  article-title: Orthopedic and surgical management of the patient with Duchenne muscular dystrophy
  publication-title: Pediatrics
– volume: 17
  start-page: 347
  year: 2018
  end-page: 361
  ident: bib0010
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
  publication-title: Lancet Neurol.
– volume: 25
  start-page: 749
  year: 2015
  end-page: 753
  ident: bib0023
  article-title: Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test
  publication-title: Neuromuscul. Disord.
– volume: 24
  start-page: 10
  year: 2014
  ident: bib0001
  article-title: A systematic review and meta-analysis of the epidemiology of Duchenne and Becker muscular dystrophy
  publication-title: Neuromuscul. Disord.
– volume: 82
  start-page: 291
  year: 2002
  end-page: 329
  ident: bib0004
  article-title: Function and genetics of dystrophin and dystrophin-related proteins in muscle
  publication-title: Physiol. Rev.
– volume: 67
  start-page: 2533
  year: 2016
  end-page: 2546
  ident: bib0008
  article-title: Dystrophin-deficient cardiomyopathy
  publication-title: J. Am. Coll. Cardiol.
– volume: 17
  start-page: 251
  year: 2018
  end-page: 267
  ident: bib0011
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
  publication-title: Lancet Neurol.
– volume: 13
  year: 2018
  ident: bib0033
  article-title: Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data
  publication-title: PLoS One
– reference: Excellence N-NIfHaC. Ataluren for Treating Duchenne Muscular Dystrophy with a Nonsense Mutation in the Dystrophin Gene. In: Excellence N-N I f H a C, 2016.
– volume: 9
  start-page: e83400
  year: 2014
  ident: bib0025
  article-title: 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes
  publication-title: PLoS One
– volume: 385
  start-page: 1748
  year: 2015
  end-page: 1757
  ident: bib0019
  article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
  publication-title: Lancet
– volume: 16
  start-page: 139
  year: 2015
  ident: bib0029
  article-title: Grip strength measured by high precision dynamometry in healthy subjects from 5 to 80 years
  publication-title: BMC Musculoskelet. Disord.
– volume: 25
  start-page: 1116
  year: 2010
  end-page: 1129
  ident: bib0005
  article-title: Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management
  publication-title: J. Child. Neurol.
– volume: 12
  start-page: 926
  year: 2002
  end-page: 929
  ident: bib0007
  article-title: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation
  publication-title: Neuromuscul. Disord.
– volume: 10
  year: 2015
  ident: bib0034
  article-title: Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial
  publication-title: PLoS One
– volume: 87
  start-page: 149
  year: 2016
  end-page: 155
  ident: bib0042
  article-title: The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 11
  year: 2016
  ident: bib0041
  article-title: Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials
  publication-title: PLoS One
– volume: 5
  year: 2016
  ident: bib0013
  article-title: Corticosteroids for the treatment of Duchenne muscular dystrophy
  publication-title: Cochrane Database Syst. Rev.
– volume: 1
  start-page: 91
  year: 2014
  end-page: 94
  ident: bib0044
  article-title: Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping
  publication-title: J. Neuromuscul. Dis.
– volume: 53
  start-page: 545
  year: 2016
  end-page: 554
  ident: bib0026
  article-title: Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy
  publication-title: Muscle Nerve
– volume: 9
  start-page: 77
  year: 2010
  end-page: 93
  ident: bib0027
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
  publication-title: Lancet Neurol.
– volume: 196
  start-page: 512
  year: 2017
  end-page: 519
  ident: bib0020
  article-title: Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary
  publication-title: Am. J. Respir. Crit. Care Med.
– volume: 49
  start-page: 473
  year: 2014
  end-page: 481
  ident: bib0036
  article-title: Respiratory muscle decline in Duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
– volume: 11
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0041
  article-title: Upper limb evaluation in Duchenne muscular dystrophy: fat-water quantification by MRI, muscle force and function define endpoints for clinical trials
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0162542
– volume: 71
  start-page: 304
  year: 2012
  ident: 10.1016/j.nmd.2019.02.002_bib0002
  article-title: Evidence-based path to newborn screening for Duchenne muscular dystrophy
  publication-title: Ann. Neurol.
  doi: 10.1002/ana.23528
– volume: 23
  start-page: 139
  year: 2013
  ident: 10.1016/j.nmd.2019.02.002_bib0028
  article-title: Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2012.10.022
– volume: 9
  start-page: 77
  year: 2010
  ident: 10.1016/j.nmd.2019.02.002_bib0027
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(09)70271-6
– ident: 10.1016/j.nmd.2019.02.002_bib0014
– volume: 385
  start-page: 1748
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0019
  article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60025-3
– volume: 13
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0033
  article-title: Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0199223
– volume: 25
  start-page: 749
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0023
  article-title: Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: a multicentric longitudinal study using the performance of upper limb test
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2015.07.009
– volume: 9
  start-page: e83400
  year: 2014
  ident: 10.1016/j.nmd.2019.02.002_bib0025
  article-title: 6 Minute walk test in Duchenne MD patients with different mutations: 12 month changes
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0083400
– volume: 40
  start-page: 1324
  year: 2012
  ident: 10.1016/j.nmd.2019.02.002_bib0032
  article-title: Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.00080312
– year: 2017
  ident: 10.1016/j.nmd.2019.02.002_bib0035
– year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0016
– volume: 21
  start-page: 396
  year: 2011
  ident: 10.1016/j.nmd.2019.02.002_bib0017
  article-title: Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2011.02.016
– volume: 23
  start-page: 682
  year: 2013
  ident: 10.1016/j.nmd.2019.02.002_bib0003
  article-title: 195th ENMC International Workshop: newborn screening for Duchenne muscular dystrophy 14–16th December, 2012, Naarden, The Netherlands
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2013.05.008
– volume: 385
  start-page: 1748
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0039
  article-title: Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60025-3
– volume: 87
  start-page: 401
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0043
  article-title: DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002891
– volume: 67
  start-page: 2533
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0008
  article-title: Dystrophin-deficient cardiomyopathy
  publication-title: J. Am. Coll. Cardiol.
  doi: 10.1016/j.jacc.2016.02.081
– volume: 17
  start-page: 347
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0010
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(18)30025-5
– volume: 53
  start-page: 545
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0026
  article-title: Reachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy
  publication-title: Muscle Nerve
  doi: 10.1002/mus.24894
– volume: 82
  start-page: 291
  year: 2002
  ident: 10.1016/j.nmd.2019.02.002_bib0004
  article-title: Function and genetics of dystrophin and dystrophin-related proteins in muscle
  publication-title: Physiol. Rev.
  doi: 10.1152/physrev.00028.2001
– volume: 35
  start-page: 126
  year: 2003
  ident: 10.1016/j.nmd.2019.02.002_bib0031
  article-title: Maximal static respiratory pressures in children and adolescents
  publication-title: Pediatr. Pulmonol.
  doi: 10.1002/ppul.10217
– volume: 24
  start-page: 10
  year: 2014
  ident: 10.1016/j.nmd.2019.02.002_bib0001
  article-title: A systematic review and meta-analysis of the epidemiology of Duchenne and Becker muscular dystrophy
  publication-title: Neuromuscul. Disord.
– volume: 196
  start-page: 512
  year: 2017
  ident: 10.1016/j.nmd.2019.02.002_bib0020
  article-title: Pulmonary endpoints in Duchenne muscular dystrophy. A workshop summary
  publication-title: Am. J. Respir. Crit. Care Med.
  doi: 10.1164/rccm.201703-0507WS
– volume: 55
  start-page: 1038
  year: 2013
  ident: 10.1016/j.nmd.2019.02.002_bib0022
  article-title: Development of the performance of the upper limb module for Duchenne muscular dystrophy
  publication-title: Dev. Med. Child Neurol.
  doi: 10.1111/dmcn.12213
– volume: 87
  start-page: 149
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0042
  article-title: The NorthStar ambulatory assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 26
  start-page: 319
  year: 2005
  ident: 10.1016/j.nmd.2019.02.002_bib0030
  article-title: Standardisation of spirometry
  publication-title: Eur. Respir. J.
  doi: 10.1183/09031936.05.00034805
– volume: 142
  start-page: S82
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0006
  article-title: Orthopedic and surgical management of the patient with Duchenne muscular dystrophy
  publication-title: Pediatrics
  doi: 10.1542/peds.2018-0333J
– volume: 24
  start-page: 201
  year: 2014
  ident: 10.1016/j.nmd.2019.02.002_bib0024
  article-title: Reliability of the performance of upper limb assessment in Duchenne muscular dystrophy
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2013.11.014
– volume: 10
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0034
  article-title: Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial
  publication-title: PLoS One
– volume: 48
  start-page: 912
  year: 2013
  ident: 10.1016/j.nmd.2019.02.002_bib0018
  article-title: Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
  doi: 10.1002/ppul.22688
– volume: 1
  start-page: 91
  year: 2014
  ident: 10.1016/j.nmd.2019.02.002_bib0044
  article-title: Prolonged ambulation in Duchenne patients with a mutation amenable to exon 44 skipping
  publication-title: J. Neuromuscul. Dis.
  doi: 10.3233/JND-140002
– ident: 10.1016/j.nmd.2019.02.002_bib0015
– volume: 5
  issue: 5
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0013
  article-title: Corticosteroids for the treatment of Duchenne muscular dystrophy
  publication-title: Cochrane Database Syst. Rev.
– volume: 16
  start-page: 139
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0029
  article-title: Grip strength measured by high precision dynamometry in healthy subjects from 5 to 80 years
  publication-title: BMC Musculoskelet. Disord.
  doi: 10.1186/s12891-015-0612-4
– volume: 17
  start-page: 445
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0012
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(18)30026-7
– volume: 2
  start-page: 269
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0045
  article-title: Non-ambulant duchenne patients theoretically treatable by exon 53 skipping have severe phenotype
  publication-title: J. Neuromuscul. Dis.
  doi: 10.3233/JND-150100
– volume: 28
  start-page: 897
  issue: 11
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0021
  article-title: Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: long-term natural history with and without glucocorticoids
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/j.nmd.2018.07.004
– volume: 49
  start-page: 473
  year: 2014
  ident: 10.1016/j.nmd.2019.02.002_bib0036
  article-title: Respiratory muscle decline in Duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
  doi: 10.1002/ppul.22847
– volume: 25
  start-page: 1116
  year: 2010
  ident: 10.1016/j.nmd.2019.02.002_bib0005
  article-title: Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management
  publication-title: J. Child. Neurol.
  doi: 10.1177/0883073810371004
– volume: 54
  start-page: 681
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0038
  article-title: Clinical trial readiness in non-ambulatory boys and men with duchenne muscular dystrophy: MDA-DMD network follow-up
  publication-title: Muscle Nerve
  doi: 10.1002/mus.25089
– volume: 50
  start-page: 487
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0037
  article-title: Characterization of pulmonary function in Duchenne muscular dystrophy
  publication-title: Pediatr. Pulmonol.
  doi: 10.1002/ppul.23172
– volume: 11
  start-page: 1475
  year: 2015
  ident: 10.1016/j.nmd.2019.02.002_bib0009
  article-title: Assessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging options
  publication-title: Ther. Clin. Risk Manag.
– volume: 12
  start-page: 926
  year: 2002
  ident: 10.1016/j.nmd.2019.02.002_bib0007
  article-title: Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation
  publication-title: Neuromuscul. Disord.
  doi: 10.1016/S0960-8966(02)00140-2
– volume: 17
  start-page: 251
  year: 2018
  ident: 10.1016/j.nmd.2019.02.002_bib0011
  article-title: Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(18)30024-3
– volume: 86
  start-page: 1022
  year: 2016
  ident: 10.1016/j.nmd.2019.02.002_bib0040
  article-title: Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy
  publication-title: Neurology
  doi: 10.1212/WNL.0000000000002464
RestrictionsOnAccess restricted access
SSID ssj0015767
Score 2.4043055
Snippet •This study contributes to the natural history of DMD, linking the ambulant and non-ambulant phases.•Respiratory measurements, upper limb function, pinch and...
The field of translational research in Duchenne muscular dystrophy (DMD) has been transformed in the last decade by a number of therapeutic targets, mostly...
SourceID liege
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 261
SubjectTerms Adolescent
Cardiovascular & respiratory systems
Child
Child, Preschool
Composite endpoint
Duchenne muscular dystrophy
Europe
forced vital capacity
Human health sciences
Humans
Male
Mobility Limitation
Motor Activity - physiology
Muscle Strength - physiology
Muscle, Skeletal - physiopathology
Muscular Dystrophy, Duchenne - complications
Muscular Dystrophy, Duchenne - physiopathology
Neurologie
Neurology
Outcome Assessment, Health Care
peak expiratory flow
Pediatrics
Prospective Studies
pulmonary function
Pédiatrie
Respiration
Respiration Disorders - etiology
Respiration Disorders - physiopathology
Respiratory Function Tests
Sciences de la santé humaine
Systèmes cardiovasculaire & respiratoire
Upper Extremity - physiopathology
Upper limb function and strength
Title Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0960896618313798
https://dx.doi.org/10.1016/j.nmd.2019.02.002
https://www.ncbi.nlm.nih.gov/pubmed/30852071
https://www.proquest.com/docview/2190120661
http://orbi.ulg.ac.be/handle/2268/244031
Volume 29
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JixUxEA7DDIgXcfe5DBE8ifF1OunN22N0eCrOQR2YW0jSydDSy-N1R_DiX_GvWkkv4mFG8NYdqiBJVSpfUksQesGTPFMZT4jNopzwIjcEzioJMQCdbWptGclQ7fMs3Z7zDxfJxQE6mXNhfFjlZPtHmx6s9dSynmZzvauq9RcPvnNA66CUlGWFT_jlPPNa_vrnEuZBAU-HlGkgJp569myGGK-28cVCaTGW7Yyv2puOau_AvhqDhr3o9Da6NYFIvBn7eQcdmPYuuvFpcpPfQ78-_3GgY9mW2O12Zo_rqlHYb2ReGFj2uHMDjNvgZrwo7HEFzY1yNUx34Gu7liwNvVP-0qbH_u4Wv3UgbjDSuHFjLCsuf_TDvgOxvcEbDGOYkzhxCFoMUaAGh3K299H56buvJ1syvcRANEzpQHJrtaXSxswYTnUGqLI0WSoZL5SxRmdRolNapnAyL0qmABJIaaiyOS8LVljKHqBD6LF5hLBUSWJzyW2iLdgPKvOyZDrjktpUK8VWKJplIPRUpty_llGLOR7tmwCxCS82EcUCxLZCLxeW3Vij4zrieBasmJNPwVwK2EGuY-IL01_a-S-2V0FzRLdXlfgeC1_LO3y7-lJILZQRAH9zARgLjOsKPZ8VTMAi954b2ZrO9SL2sM0X3geah6PmLSNlAJpjAIqP_6-PT9BN_zcGIz1Fh8PemWeAswZ1HBbSMTravP-4PfsNMBwquA
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbKrgRcUHkvtGAkToho83ASh9uqpdrSdg_QSr1ZtmNXQXmsNjESv4a_yth5IA4tErfI8Ui2Zzz-7Bl_Rug9iWkqUhJ7OvWpRzKqPNirxJ4C6KwTrXOfO7bPTbK-Il-u4-s9dDTehbFplYPv732689ZDyXIYzeW2KJbfLPimgNbBKIMozeg9NLfsVPEMzVenZ-vNFEwASO1uTUN9zwqMwU2X5lVXli80yHrmzvC25Wle2hj27TDULUcn--jRgCPxqm_qY7Sn6ifo_sUQKX-Kfn39E0PHvM6x2W7VDpdFJbBdy6w-MG9xYzrousJVf1bY4gKKK2FKGHEnVze1NxW0Rthzmxbb41t8bEDj4KdxZfp0Vpz_bLtdA5r7hFcY-jDe48Qub9ElgirsGG2foauTz5dHa294jMGThKSdR7WWOuA6jJQigUwBWOYqTXhEMqG0kqkfyyTIE9icZ3kkABVwrgKhKcmzKNNB9BzNoMXqJcJcxLGmnOhYanAhAad5HsmU8EAnUohogfxRB0wOTOX2wYySjSlp3xmojVm1MT9koLYF-jCJbHuajrsqh6Ni2Xj_FDwmg0XkLiEyCf1loP8S--gshzU7UbAfIbN03u7blDeMSyYUAwRMGcAs8K8L9G40MAbz3AZveK0a07LQIjfLvQ91XvSWN_U0AtwcAlZ89X9tfIserC8vztn56ebsNXpo__S5SQdo1u2MOgTY1Yk3w7T6DUrjLWk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Respiratory+and+upper+limb+function+as+outcome+measures+in+ambulant+and+non-ambulant+subjects+with+Duchenne+muscular+dystrophy%3A+A+prospective+multicentre+study&rft.jtitle=Neuromuscular+disorders+%3A+NMD&rft.au=Ricotti%2C+V&rft.au=Selby%2C+V&rft.au=Ridout%2C+D&rft.au=Domingos%2C+J&rft.date=2019-04-01&rft.issn=1873-2364&rft.eissn=1873-2364&rft.volume=29&rft.issue=4&rft.spage=261&rft_id=info:doi/10.1016%2Fj.nmd.2019.02.002&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0960-8966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0960-8966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0960-8966&client=summon